The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis.
AffiliationDepartment of Respiratory Medicine, Cork University Hospital, Cork, Ireland. email@example.com
MetadataShow full item record
CitationThe use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis. 2010, 65 (6):545-6 Thorax
AbstractA case of debilitating cavitating lung disease associated with rheumatoid arthritis and bronchocentric granulomatosis, which failed to respond to conventional medical or surgical treatment, is described. The patient was treated over 10 years with steroids, antimicrobial agents, disease-modifying antirheumatoid drugs and surgery. Lung function continued to decline and the patient presented for admission with recurrent pneumonia. Abatacept was initiated to modify the underlying immunopathology. Following 12 months of treatment with abatacept the patient has demonstrable improvement in lung function and lung anatomy, and has not presented to hospital with pneumonia. She has tolerated the treatment without complication. The use of abatacept has stabilised the lung disease in this case in the medium term and prevented readmission to hospital. These results suggest a larger role for abatacept in those with such disease in the future and may warrant further investigation.
- Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
- Authors: Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M
- Issue date: 2008 Apr
- Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
- Authors: Massarotti EM
- Issue date: 2008 Mar
- Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
- Authors: Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E
- Issue date: 2006 Sep
- Safety profile of abatacept in rheumatoid arthritis: a review.
- Authors: Khraishi M, Russell A, Olszynski WP
- Issue date: 2010 Oct
- Role of abatacept in the management of rheumatoid arthritis.
- Authors: Nogid A, Pham DQ
- Issue date: 2006 Nov